Effect of the synthetic lipid A-related compound, DT-5461, on resistance to Sendai virus infection in mice.
DT-5461 enhanced host resistance to Sendai virus infection in mice. Intranasal (i.n.) administration of 200 micrograms of DT-5461 per mouse 3 days before infection was the most effective administration route, dose and timing. DT-5461 enhanced the cytotoxicity of murine natural killer (NK) cells. In addition, DT-5461 activated murine peritoneal macrophages, resulted in augmented of cytotoxicity and the induction of tumor necrosis factor-alpha (TNF-alpha). Therefore, these immunomodulating activities presented by DT-5461 caused protection against Sendai virus infection.
Yoshida
R
R
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
Sato
K
K
Yoo
Y C
YC
Yoshimatsu
K
K
Tamura
M
M
Ishihara
C
C
Arikawa
J
J
Azuma
I
I
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002240:Carbohydrate Sequence; D003601:Cytotoxicity Tests, Immunologic; D004187:Disaccharides / Q000494:pharmacology*; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects; D007694:Killer Cells, Natural / Q000276:immunology; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D010222:Parainfluenza Virus 1, Human / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000276:Adjuvants, Immunologic; D004187:Disaccharides; D008050:Lipid A; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C077208:DT 5461